BG
TVRD

BlackRock Group’s Tvardi Therapeutics TVRD Stock Holding History

BlackRock Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-84
Closed -$19K – 3055
2016
Q1 		$19K Sell
84
-200
-70% -$59.7K ﹤0.01% 3030
2015
Q4 		$172K Hold
284
– – ﹤0.01% 2559
2015
Q3 		$146K Sell
284
-54
-16% -$36.1K ﹤0.01% 2610
2015
Q2 		$148K Buy
+338
New +$131K ﹤0.01% 2654

Other funds holding TVRD

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Group's TVRD Position: Q2 2016 in Review

BlackRock Group sold out of Tvardi Therapeutics (TVRD) in Q2 2016, closing a stake of 84 shares — an estimated $19K sold.

BlackRock Group first reported a position in TVRD in Q2 2015 and held it in 4 quarters. The position peaked at $172K in Q4 2015. 70 funds tracked by Wall St. Rank hold TVRD as of Q2 2016.

  • BlackRock Group reported no remaining Tvardi Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Group sold 84 Tvardi Therapeutics shares in Q2 2016, an estimated $19K.
  • BlackRock Group first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 4 quarters.
  • BlackRock Group's Tvardi Therapeutics position peaked at $172K in Q4 2015.
  • 70 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.